A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 weeks in Subjects with Chronic HCV and HIV-1 Coinfection

Investigator: Anne Luetkemeyer, MD
Sponsor: Gilead Sciences, Inc.

Location(s): United States


This study will evaluate the antiviral efficacy, safety and tolerability of sofosbuvir (SOF)/velpatasvir (VEL; GS-5816) fixed dose combination (FDC) administered for 12 weeks in HCV treatment-naive and treatment-experienced (including treatment intolerant) adults with chronic HCV infection who are coinfected with HIV-1.